{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:02:06Z","timestamp":1791115326006,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.beha.2012.04.005","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T11:33:49Z","timestamp":1337686429000},"page":"185-190","source":"Crossref","is-referenced-by-count":13,"title":["The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL)"],"prefix":"10.1016","volume":"25","author":[{"given":"Richa","family":"Dawar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.beha.2012.04.005_bib1","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3322\/caac.20073","article-title":"Cancer statistics","volume":"60","author":"Jemal","year":"2010","journal-title":"CA\u2013Cancer J Clin"},{"issue":"4","key":"10.1016\/j.beha.2012.04.005_bib2","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.beha.2012.04.005_bib3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1182\/asheducation-2009.1.523","article-title":"The 2008 WHO classification of lymphomas: implications for clinical practice and translational research","author":"Jaffe","year":"2009","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"10.1016\/j.beha.2012.04.005_bib4","unstructured":"Goy A, Kahl B. Mantle cell lymphoma: the promise of new treatment options. Crit Rev Oncol Hematol. Dec 16."},{"issue":"1","key":"10.1016\/j.beha.2012.04.005_bib5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hon.767","article-title":"Update on the molecular biology of mantle cell lymphoma","volume":"24","author":"Bertoni","year":"2006","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.beha.2012.04.005_bib6","doi-asserted-by":"crossref","unstructured":"Dreyling M, Hoster E, Bea S, et\u00a0al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma (MCL): minutes of the 9th European MCL Network conference. Leuk lymphoma. Sep;51(9):1612\u20131622.","DOI":"10.3109\/10428194.2010.496507"},{"issue":"10","key":"10.1016\/j.beha.2012.04.005_bib7","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.beha.2012.04.005_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00277-003-0774-2","article-title":"Mantle cell lymphoma: established therapeutic options and future directions","volume":"83","author":"Lenz","year":"2004","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.beha.2012.04.005_bib9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/1096-8652(200007)64:3<190::AID-AJH9>3.0.CO;2-B","article-title":"Mantle cell lymphoma. A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group","volume":"64","author":"Weisenburger","year":"2000","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.beha.2012.04.005_bib10","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2012.04.005_bib11","doi-asserted-by":"crossref","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","article-title":"Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha","volume":"163","author":"Corral","year":"1999","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.beha.2012.04.005_bib12","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production","volume":"9","author":"Muller","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"10.1016\/j.beha.2012.04.005_bib13","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1182\/blood-2003-02-0361","article-title":"Immunomodulatory drug costimulates T cells via the B7-CD28 pathway","volume":"103","author":"LeBlanc","year":"2004","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.beha.2012.04.005_bib14","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1158\/1078-0432.CCR-05-0577","article-title":"Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model","volume":"11","author":"Hernandez-Ilizaliturri","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.beha.2012.04.005_bib15","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.leukres.2006.01.010","article-title":"Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly","volume":"30","author":"Gandhi","year":"2006","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.beha.2012.04.005_bib16","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in\u00a0vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.beha.2012.04.005_bib17","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.beha.2012.04.005_bib18","doi-asserted-by":"crossref","first-page":"7347","DOI":"10.1158\/0008-5472.CAN-08-4898","article-title":"Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism","volume":"69","author":"Escoubet-Lozach","year":"2009","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.beha.2012.04.005_bib19","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.21468","article-title":"Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in\u00a0vitro and in\u00a0vivo","volume":"84","author":"Zhang","year":"2009","journal-title":"Am J Hematol"},{"issue":"21","key":"10.1016\/j.beha.2012.04.005_bib20","doi-asserted-by":"crossref","first-page":"4713","DOI":"10.1182\/blood-2009-04-217687","article-title":"Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy","volume":"114","author":"Ramsay","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2012.04.005_bib21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J Hematol Oncol"},{"issue":"30","key":"10.1016\/j.beha.2012.04.005_bib22","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2012.04.005_bib23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.beha.2012.04.005_bib24","first-page":"268","article-title":"Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse Large-B-cell lymphoma: results of an international study (NHL-003)","volume":"112","author":"Czuczman","year":"2008","journal-title":"ASH Annu Meet Abstr"},{"issue":"11","key":"10.1016\/j.beha.2012.04.005_bib25","first-page":"262","article-title":"Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003)","volume":"112","author":"Zinzani","year":"2008","journal-title":"ASH Annu Meet Abstr"},{"key":"10.1016\/j.beha.2012.04.005_bib26","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1182\/blood.V114.22.2719.2719","article-title":"A phase I\/II study of lenalidomide in combination with rituximab in relapsed\/refractory mantle cell lymphoma","volume":"114","author":"Wang","year":"2009","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2012.04.005_bib27","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.beha.2012.04.005_bib28","first-page":"724","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"24","author":"Romaguera","year":"2006","journal-title":"Erratum Appears J Clin Oncol"},{"issue":"3","key":"10.1016\/j.beha.2012.04.005_bib29","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.leukres.2010.09.027","article-title":"Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in\u00a0vitro and in\u00a0vivo","volume":"35","author":"Qian","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2012.04.005_bib30","unstructured":"Zaja F, De Luca S, Vitolo U, et\u00a0al. Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neoangiogenic biomarkers. Haematologica. Nov 4."},{"key":"10.1016\/j.beha.2012.04.005_bib31","first-page":"2700","article-title":"Lenalidomide, bendamustine, and rituximab as first-line therapy for patients > 65 Years with mantle cell lymphoma: results from the phase I Portion of the Nordic lymphoma group MCL4 (LENA-BERIT) trial","volume":"118","author":"Jerkeman","year":"2011","journal-title":"Blood (ASH Annu Meet Abstracts)"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692612000321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T18:35:59Z","timestamp":1713983759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692612000321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1521692612000321"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2012.04.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}